SEC Form 4 · accession 0001104659-16-160115
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Aryeh
Director
Period of report
Nov 29, 2016
Accepted (ET)
Dec 1, 2016 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, without par value | Nov 29, 2016 | A | 1,136,363 | $1.76 | A | 1,210,363 | D | |
| Common Shares, without par valueF1,F4 | Nov 29, 2016 | A | 175,979 | — | A | 637,457 | I | By JALAA Equities, L.P. |
| Common Shares, without par valueF2,F4 | Nov 29, 2016 | A | 31,280 | — | A | 31,280 | I | By JLV Investments, LP |
| Common Shares, without par valueF3,F4 | Nov 29, 2016 | A | 82,765 | — | A | 82,765 | I | By JLD Investments, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Received in exchange for 171,587 shares of Aegerion Pharmaceuticals, Inc. ("Aegerion") common stock pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, Aegerion and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into Aegerion, effective November 29, 2016. On the date prior to the effective time of the merger, the closing price of Aegerion's common stock was $1.87 per share and the closing price of the Issuer's common shares was $1.83 per share.
- F2Received in exchange for 30,500 shares of Aegerion common stock pursuant to the Merger Agreement.
- F3Received in exchange for 80,700 shares of Aegerion common stock pursuant to the Merger Agreement.
- F4The Reporting Person disclaims beneficial ownership except to the extent of the Reporting Person's pecuniary interest.